Scuttlebutt

Scuttlebutt

Tempus AI CEO on its data arm: "it would probably trade at 20 or 30 or 40 times revenue"

10 takeaways: why Tempus is buying Personalis for $1.5B to enter MRD testing, what "mowing 8,000 lawns" means for its data moat, and why AI has helped patients more than doctors

Scuttlebutt's avatar
Scuttlebutt
Nov 21, 2026
∙ Paid

After Earnings · Nov 20, 2026 · 31m · 23m saved

With Eric Lefkofsky, Founder and CEO of Tempus AI

Tempus AI CEO on its data arm: "it would probably trade at 20 or 30 or 40 times revenue"

Tempus AI holds more than 600 petabytes of matched clinical and molecular data, and it grew by 50 petabytes last quarter alone, Eric Lefkofsky, founder and CEO of Tempus AI, told Austin Hankwitz on After Earnings. Tempus is now paying about $1.5 billion for Personalis to move into blood tests that catch returning cancer early.

Public investors mostly value Tempus as a diagnostics company that sequences patients and bills insurers. Eric says that view ignores the second half of the business, which licenses data to drugmakers and would be worth far more on its own.

"A significant number of investors historically have not appreciated the strength of our data business. They've discounted it to like zero." — Eric Lefkofsky

Eric built Tempus's data pipes into more than 8,000 hospitals, one at a time, and now runs two large clusters of Nvidia chips to train models on what comes back.

The full interview is covered here so you can skip it. 31 minutes of audio, 8 minutes of reading.

Here are the 10 takeaways that matter.


This Scuttlebutt Summary is available in full to premium subscribers. If you're not one already, please consider subscribing to keep reading.


Key Takeaways

  • Tempus makes money two ways: sequencing cancer patients, and licensing the data to drugmakers

  • Its dataset is more than 600 petabytes, built through pipes into over 8,000 hospitals

  • The $1.5B Personalis deal is a bet on MRD, blood tests that find cancer before a scan does

    • Eric would not be surprised if MRD volume one day passes Tempus's therapy-selection work

  • AI has made patients smarter but not yet doctors, and Tempus's Hub platform is aimed at the gap

  • Drugmakers pay because most oncology trials fail, and Tempus data helps design better ones

  • Eric says investors value the data business at close to zero, while a standalone version would trade like tech

1. Sequencing Plus Data

Eric opened by explaining that Tempus runs two businesses that feed each other. One sequences patients and bills insurers. The other licenses the de-identified results to drug and biotech companies building AI models.

Eric Lefkofsky says Tempus marries sequencing with clinical records

"We make money two ways. We are one of the largest sequencers of patients, particularly cancer patients, in the world... but we also marry that data with clinical data... and we have a very big data and AI modeling business." — Eric Lefkofsky

The sequencing side began with matching patients to targeted cancer drugs. Tempus reported third-quarter revenue of $411.5 million, up 23% from a year earlier, with data and applications revenue up 33%. Adjusted EBITDA rose from $1.5 million a year ago to $25.5 million. Eric tied the data growth to drugmakers building their own large-language-model capabilities over the past three-plus years, which made them hungrier for matched datasets like Tempus's.

2. Mowing 8,000 Lawns

User's avatar

Continue reading this post for free, courtesy of Scuttlebutt.

Or purchase a paid subscription.
© 2026 The Golden Age LLC · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.